Kyle Bass Lives Up To Big Pharma Patent Challange

HFA Padded
Mark Melin
Published on
Updated on

Legal papers from Kyle Bass-backed group challenge biotech company on their patents Kyle Bass, founder of Dallas-based hedge fund Hayman Capital Management, appears to be making good on his announced plans to play Robin Hood with the top pharmaceutical companies. Bass has now filed his first Inter Partes Review, a legal move challenging big pharma and their control over drug distribution and prices. His first target: Acorda Therapeutics, a biotechnology company based in Ardsley, New York. Their drugs primarily target neurological functions in people with multiple sclerosis.   Kyle Bass-backed legal challenge underway In a legal challenge taken on behalf of…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.